Pancreatic ctDNA Monitoring for Early Recurrence Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and treating pancreatic cancer are inadequate, with few genetic alterations effectively utilized in clinical care, leading to high mortality rates.
Innovation Solution
Characterizing pancreatic adenocarcinoma through testing for somatic mutations in chromatin regulating genes like MLL, MLL2, MLL3, and ARID1A, and analyzing cell-free tumor DNA in plasma for early detection and prognosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current genetic alteration detection methods are used, then diagnostic capability is limited, but mortality rate remains high
Solution Approach 1:
The patent segments the detection process into multiple stages: initial screening using ctDNA analysis of plasma samples, followed by confirmatory testing using tissue biopsy samples. This segmentation allows for early detection in high-risk patients while maintaining diagnostic accuracy through multi-stage verification, directly addressing the contradiction between limited detection capability and high mortality rate
Solution Approach 2:
The patent implements preliminary action by performing genetic alteration detection on ctDNA in plasma samples before clinical symptoms manifest or before traditional diagnostic methods are applied. This preliminary detection enables early intervention and treatment planning, reducing mortality by catching pancreatic cancer at earlier, more treatable stages
2Measurement precision
If comprehensive genetic testing is performed, then diagnostic accuracy improves, but clinical utility remains limited
Solution Approach 1:
The patent applies local quality by focusing genetic testing on specific high-impact gene alterations (KRAS, NRAS, BRAF, TP53, SMAD4, CDKN2A) rather than performing comprehensive whole-genome sequencing. This targeted approach maintains diagnostic accuracy for clinically actionable mutations while improving adaptability to current clinical workflows and resource constraints
Solution Approach 2:
The patent changes the parameter of sample type from traditional tissue biopsy alone to include both plasma ctDNA and tissue samples. This parameter change enables non-invasive preliminary testing that can triage patients for further diagnostic workup, improving both diagnostic accuracy and clinical utility by making comprehensive testing more accessible
3Measurement precision
If tissue biopsy is used for genetic testing, then diagnostic specificity is high, but patient burden and procedural complexity increase
Solution Approach 1:
The patent introduces plasma ctDNA as an intermediary sample type that bridges the gap between non-invasive blood draws and invasive tissue biopsies. The ctDNA serves as a preliminary indicator of genetic alterations, allowing clinicians to identify patients who would benefit from tissue biopsy while reducing the number of patients requiring invasive procedures, thus maintaining specificity while improving ease of operation
Solution Approach 2:
The patent performs preliminary genetic screening using plasma ctDNA before proceeding to tissue biopsy. This preliminary action identifies patients with high probability of specific mutations, allowing for targeted tissue sampling and reducing the overall burden of invasive procedures while maintaining high diagnostic specificity through the two-stage approach
Data Source
AI summary
Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.